Ain Holdings Inc. · TSE:9627
Ain — Ain Pharmaciez — FY4/14 Earnings Presentation
13 slides from Ain's earnings presentation, Jun 5, 2014
Slide 1: FY4/14 Results Briefing
FY4/14 Results Briefing June 5,2014
Slide 2: Result Overview
Result Overview © 2014 AIN PHARMACIEZ Inc. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L The Group reported net sales of ¥170,225 million, an increase of 10.1% year on year, reflecting the opening of new dispensing pharmacies and M&As. Ordinary income rose 2.9% to ¥10,587 million and net income increased 3.6% year on year to ¥5,259 million. FY4/13 FY4/14 FY4/14 YoY YoY
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business(Consolidated) The dispensing pharmacy business reported net sales of ¥151,472 million, an increase of 10.3% year on year, and segment income of ¥12,772 million, up 0.9%. FY4/13 FY4/14 FY4/14 YoY YoY Vs plan (¥ million) results plan results change change(%) (%) Net sales
Slide 5: Drug and Cosmetic Store Business (Consolidated)
Drug and Cosmetic Store Business(Consolidated) The drug and cosmetic store business reported net sales of ¥17,985 million, an increase of 7.5% year on year, and segment income of ¥23million, up 65.8%. FY4/13 FY4/14 FY4/14 YoY YoY Vs plan (¥ million) results plan results change change(%) (%) Net sale
Slide 6: Consolidated B/S
Consolidated B/S The shareholders’ equity ratio improved 1.5 percentage points to 41.5%, compared with 40.0% at the end of the previous fiscal year. (¥ million) (¥ million) End-FY4/13 End-FY4/14 Assets Liabilities Assets Liabilities Current Current Current assets 45,686 Current assets 50,349 43,162
Slide 7: Assets
Assets Consolidated current assets at the end of the fiscal year under review increased by ¥1,172 million to ¥44,334 million compared to ¥43,162 million at the end of the previous fiscal year. Fixed assets at the end of the fiscal year under review increased by ¥4,371 million to ¥57,048 million comp
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets Liabilities increased by ¥1,659 million to ¥59,142 million compared to ¥57,483 million at the end of the previous fiscal year. This primarily reflected accounts payable of ¥28,002 million, up ¥3,917 million year on year, short-term debt of ¥6,535 million, down ¥947 million
Slide 9: Consolidated C/F
Consolidated C/F Cash and cash equivalents increased ¥296 million year on year to ¥18,735 million. (¥ million) End-FY4/13 End-FY4/14 Change Net cash provided by operating activities 10,203 14,662 +4,459 Income before income taxes and minority interests 9,694 10,265 +571 Depreciation and amortization
Slide 10: Business Value Analysis
Business Value Analysis End-FY4/12 End-FY4/13 End-FY4/14 Change Shareholders’ equity ratio (%) 39.2 40.0 41.5 +1.5 Market value equity ratio (%) 79.6 79.3 70.3 (9.0) PER (times) 13.96 14.97 13.62 (1.35) EPS (¥) 307.35 318.37 330.08 +11.71 PBR (times) 2.03 1.98 1.70 (0.28) BPS (¥) 2,113.79 2,403.43 2
Slide 11: FY4/15 Plan (Consolidated)
FY4/15 Plan (Consolidated) The Group forecasts net sales for the fiscal year ending April 30, 2015 of ¥190,000 million, up 11.6% year on year, ordinary income of ¥10,700 million, up 1.1%, and net income of ¥5,500 million, an increase of 4.6% FY4/13 FY4/14 FY4/15 YoY YoY (¥ million) results results p
Slide 12: Inquiries: AIN PHARMACIEZ Corporate Planning Division
Inquiries related to this presentation should be addressed to AIN PHARMACIEZ INC. Corporate Planning Division TEL(81)11-814-0010 FAX(81)11-814-5550 http://www.ainj.co.jp/ This document may not be reproduced or distributed to any third party without prior approval of AIN PHARMACIEZ INC. This document
Slide 13: AIN GROUP
AIN GROUP